Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V. Heppt(Universitätsklinikum Erlangen), Carola Berking(Universitätsklinikum Erlangen), Rudolf Herbst(Helios Klinikum Erfurt), Susanne G. Schäd(University of Rostock), Julia K. Tietze(LMU Klinikum), Markus Meißner(Goethe University Frankfurt), Daniela Göppner(Universitätsklinikum Gießen und Marburg), Sebastian Haferkamp(University Hospital Regensburg), Andrea Forschner(University of Tübingen), David Rafei‐Shamsabadi(University Medical Center Freiburg), C. Schmid-Tannwald(LMU Klinikum), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Friedegund Meier(National Center for Tumor Diseases), Lucie Heinzerling(LMU Klinikum), Michael Constantin Kirchberger(Friedrich-Alexander-Universität Erlangen-Nürnberg), Thomas Eigentler(University Children's Hospital Tübingen), Irmgard Bumeder(LMU Klinikum), Christiane Pfeiffer(University Hospital Augsburg), Carmen Loquai(Johannes Gutenberg University Mainz), Mirjana Ziemer(University Medical Center), Felix Kiecker(Humboldt-Universität zu Berlin), Beatrice Schell(SRH Wald-Klinikum Gera), Patrick Terheyden(University Hospital Schleswig-Holstein), Margit A. Huber(Universität Ulm), Jochen Utikal(German Cancer Research Center)
Cited by 203
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k